Research programme: CNS disorders therapeutics - Bayer Schering Pharma/MedImmune

Drug Profile

Research programme: CNS disorders therapeutics - Bayer Schering Pharma/MedImmune

Alternative Names: Proteases - Bayer Schering Pharma/MedImmune

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Direvo Biotech
  • Developer Bayer Schering Pharma; MedImmune
  • Class Peptide hydrolases
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported CNS disorders

Most Recent Events

  • 30 Sep 2008 DIREVO Biotech has been acquired and merged into Bayer Schering Pharma
  • 29 Jan 2008 Early research in CNS disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top